Endovascular Coiling Using Target Tetra® Coils for Small Intracranial Aneurysm
NCT ID: NCT06064435
Last Updated: 2023-12-18
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
NOT_YET_RECRUITING
100 participants
OBSERVATIONAL
2023-12-31
2026-03-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
* Enrollment of patients: The following process is carried out for patients who have consented to participate in the study among non-ruptured or ruptured cerebral aneurysm patients selected based on the inclusion and exclusion criteria.
* Before the procedure, the following items are verified:
* Informed consent form
* Demographic information
* Past medical history and family history
* Vital signs
* Electrocardiogram (ECG) results (results from within the previous 12 weeks before the screening visit can be used)
* Laboratory test results (results from within the previous 12 weeks before the screening visit can be used): WBC, RBC, Hb, Hct, platelet count, PT INR, aPTT, cholesterol, ALP, AST, ALT, albumin, total bilirubin, total protein, BUN, creatinine, eGFR\*, Urine-HCG†, FBS, triglycerides, LDL, PRU (VerifyNow test), and ARU (VerifyNow test) \*eGFR = (140 - age) x (weight/72) x Creatinine
* Pregnancy test (if applicable)
* Imaging findings (results from within the previous 1 year before the screening visit can be used)
* Adverse events
* Concomitant medications/therapies
* Pre-procedure modified Rankin Scale (mRS) assessment
③ Following the established method, coil embolization is performed under general anesthesia, and mechanical or technical failures of the Target Tetra® Detachable Coil occurring during the treatment are investigated.
* Failure to advance or insert
* Stretch
* Disconnection
* Detachment failure
* Material deformation
* Difficult to remove
* Peeled or delaminated device
* Premature detachment ④ During the procedure and within 30 days post-procedure, neurological and non-neurological complications are investigated.
* Neurological complications
-Any cause of death
* Any intracranial thromboembolism (asymptomatic or symptomatic)
* Any intracranial hemorrhage including aneurysm perforation
* Any intracranial vessel injury
* Miscellaneous: any ocular hemorrhage
* Non-neurological complications
-Puncture site complication requiring any intervention
-Pseudoaneurysm
-Arteriovenous (AV) fistula
-Hematoma requiring transfusion
-Retroperitoneal hemorrhage
-Arterial dissection
* Thromboembolism including limb ischemia
* Miscellaneous: infection, vessel rupture/perforation
* Complications related to general anesthesia
* After the procedure, the occlusion rate of cerebral aneurysms (modified Raymond Scale; complete occlusion, neck remnant, sac remnant) and packing density are evaluated.
* Modified Raymond Scale
* Packing Density Packing Density = Volume of coils placed in the aneurysm / Volume of the aneurysm measured on a 3D workstation (%) The above process is conducted through the open-source Angiosuite application.
⑥ Characteristics of cerebral aneurysms in patients who have been treated with Target Tetra® Detachable Coils in over 70% of the total packing density are identified.
⑦ Clinical outcomes (mRS) are evaluated at 1 month, 6 months, 12 months of follow-up.
\<Modified Rankin Scale score\>
⑧ At 6 months, 12 months, the occlusion rate of cerebral aneurysms (Modified Raymond Scale) and recurrence are assessed by at least two neurosurgery specialists using 3T-MR angiography or cerebral angiography.
⑨ Patients who have not been treated with Target Tetra® Detachable Coils in over 70% of the total packing density are excluded from the analysis.
The independent Study Monitoring will be regularly proceed and processed on the basis of the permission of instituitional review board.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Tetral Coil Group
Intracranial Aneurysm patients who treated with Target Tetra® coils (70% or more of packing density)
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Patients with intracranial aneurysms suitable for endovascular embolization therapy with a maximum diameter of 5mm or less
3. Including both ruptured and unruptured intracranial aneurysms
4. Patients for whom the use of Target Tetra® coil is expected in endovascular coil embolization therapy
5. Patients who have undergone balloon-assisted coiling or adjunctive stent placement during coil embolization
6. Subjects who have received an explanation of the clinical study and provided written consent to participate in the study
Exclusion Criteria
2. Infectious, dissecting, traumatic, or mycotic aneurysms
3. Patients who have undergone surgical or endovascular treatment for the target intracranial aneurysm
4. Patients in whom vascular access to the target intracranial aneurysm is not possible due to conditions such as moyamoya disease, dural arteriovenous malformation, significant atherosclerotic stenosis, or severe vessel tortuosity
5. Patients with ruptured intracranial aneurysms classified as Hunt and Hess grade 5 (deep coma)
6. Patients with hypersensitivity reactions to the materials used in the coils, such as platinum, tungsten, nickel, or stainless steel
7. Patients with serious adverse reactions to contrast agents
8. Patients who are unable to complete planned follow-up observations due to expected short-term survival or comorbidities
9. Female patients who are pregnant (positive pregnancy test) or planning pregnancy within 12 months after coil placement, or breastfeeding
10. Patients with significant renal dysfunction or uncorrected coagulation disorders
19 Years
80 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Yonsei University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Keunyoung PARK, M.D.PhD.
Role: PRINCIPAL_INVESTIGATOR
Department of Neurosurgery, Yonsei University College of Medicine, Severance Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Severance Hospital
Seoul, , South Korea
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Keunyoung PARK, M.D.PhD.
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
1-2023-0053
Identifier Type: -
Identifier Source: org_study_id